Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03532217 |
Title | Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer |
Recruitment | Active, not recruiting |
Gender | male |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Washington University School of Medicine |
Indications | |
Therapies |
Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM |
Age Groups: | senior | adult |
Covered Countries | USA |